pimozide has been researched along with clarithromycin in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 8 (57.14) | 29.6817 |
2010's | 5 (35.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Keserü, GM | 1 |
Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Jia, L; Sun, H | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Desta, Z; Flockhart, DA; Kerbusch, T | 1 |
Babb, VJ; Drici, MD; Flockhart, DA; Kerbusch, T; Mahal, SK; Pearle, PL; Richard, E; Soukhova, N | 1 |
1 review(s) available for pimozide and clarithromycin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for pimozide and clarithromycin
Article | Year |
---|---|
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2D6; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Heart Conduction System; Humans; Male; Middle Aged; Pimozide; Protein Synthesis Inhibitors; Reference Values; Sex Factors; Time Factors | 1999 |
12 other study(ies) available for pimozide and clarithromycin
Article | Year |
---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Antipsychotic Agents; Area Under Curve; Biotransformation; Child; Child, Preschool; Clarithromycin; Cytochrome P-450 CYP2D6; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Electrophysiology; Female; Genotype; Humans; Male; Microsomes, Liver; Middle Aged; Pimozide; Rabbits; Tourette Syndrome | 2000 |